Pharmaceuticals

CR Double-Crane

CHINA RESOURCES PHARMACEUTICAL SUB-HUANQIUSHANSEAH REPORTS DECREASE IN REVENUE AND PROFIT IN Q1 2026

CR Double-Crane released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 2.807 B, actual EPS CNY 0.4679

CR Double-Crane FY2026 Q1 Earnings Release on April 25, 2026 After-Market (BJT)

CR Double-Crane released FY2025 earnings on March 19 After-Market (BJT), actual revenue CNY 11 B (forecast CNY 11.63 B), actual EPS CNY 1.5928 (forecast CNY 1.6733)

CR Double-Crane released FY2025 Q4 earnings on March 19 After-Market (BJT), actual revenue CNY 2.718 B, actual EPS CNY 0.2871

CR Double-Crane to Release FY2025 Annual Earnings on March 20, After-Market (BJT), Forecast Revenue CNY 11.63 B, EPS CNY 1.6733

CR Double-Crane released FY2025 9 Months earnings on October 21 After-Market (BJT), actual revenue CNY 8.283 B, actual EPS CNY 1.3069

CR Double-Crane released FY2025 Q3 earnings on October 21 After-Market BJT, actual revenue CNY 2.542 B, actual EPS CNY 0.3588

CR Double-Crane FY2025 Q3 Earnings Release on October 25 After-Market (BJT)

CR Double-Crane released FY2025 Semi-Annual Earnings on August 22 After-Market (BJT), actual revenue CNY 5.742 B, actual EPS CNY 0.948

CR Double-Crane released FY2025 Q2 earnings on August 22 After-Market BJT, actual revenue CNY 2.663 B, actual EPS CNY 0.4548

CR Double-Crane to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Chuangyuan Shuanghe Plans to Set Up Biopharmaceutical Industry Fund

China Resources Double Crane to Invest 40 Million in Medical Innovation Fund

CHINA RESOURCES DOUBLE CRANE STEADILY EXPANDS INNOVATION DRUG PIPELINE

Huarenshuanghe Receives Approval for Compound Amino Acid Injection from National Medical Products Administration

Huachang Shuanghe Receives Pharmaceutical GMP Compliance Notice

Huaron Pharmaceutical's Subsidiary Xiangzhong Pharmaceutical Obtains Drug Registration Certificate for Vortioxetine Hydrobromide Tablets

Huarun Double Crane's Subsidiary Anhui Double Crane Obtains Pharmaceutical GMP Compliance Notice

Huaren Zizhu's Dienogest Tablets Obtain Russia Drug Registration Certificate

03320

600062

002886

China Resources Pharma's Shenzhou Biotech, a subsidiary of CR Double-Crane, has made significant breakthroughs in the industrial application of synthetic biology. The core product, 1,4-butanediamine, has been successfully integrated into WOTE's newly launched Wouper PA46 bio-based high-performance polyamide material system. This marks the entry of China Resources Pharma's products into the high-performance materials application field. Wouper PA46 boasts multiple excellent properties, making it suitable for high-end manufacturing sectors such as automotive transmission systems and precision electronics, demonstrating strong downstream application potential

AASTOCKS

CHINARES PHARMA

WOTE

CHINARES PHARMA introduces new product system for downstream customers under 1,4-Butanediamine

01313

00836

01109

02460

00291

01515

Han Song, a member of the Party Committee and Deputy General Manager of China Resources (Group) Co., Ltd., is suspected of serious violations of discipline and law, has voluntarily surrendered, and is currently undergoing disciplinary review and supervisory investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission. (CCTV News)

Wallstreetcn

CR BLDG MAT TEC

CHINA RES POWER

CHINA RES LAND

CR BEVERAGE

CHINA RES BEER

CR MEDICAL

Han Song, Deputy General Manager of China Resources Group, is under investigation

CR Double-Crane announced that the company and some of its subsidiaries participated in the 11th batch of national centralized drug procurement, and some products are expected to be selected. The drugs expected to be selected include Metoclopramide Injection, Meprobamate Injection, Famotidine Injection, and Piracetam Oral Immediate Release Formulation. Among them, the expected selected price for Metoclopramide Injection is 0.68 yuan per unit, for Meprobamate Injection is 9.78 yuan per unit, for Famotidine Injection is 0.42 yuan per unit, and for Piracetam Oral Immediate Release Formulation is 7.87 yuan per bottle

Zhitong

CR Double-Crane: Some drugs are proposed to be selected for national centralized drug procurement

According to the Zhitong Finance APP, CR Pharmaceutical announced that CR Double-Crane achieved a total operating revenue of 8.283 billion yuan (RMB, the same below) for the nine months ending September 30, 2025, a year-on-year decrease of 3.1%; net profit was 1.388 billion yuan, a year-on-year decrease of 1.7%

CR Pharmaceutical: CR Double-Crane's net profit for the first three quarters is 1.388 billion yuan, a year-on-year decrease of 1.7%

CR Double-Crane announced that its revenue for the third quarter was 2.542 billion yuan, a year-on-year decrease of 2.96%; net profit was 374 million yuan, a year-on-year increase of 6.71%. Revenue for the first three quarters was 8.283 billion yuan, a year-on-year decrease of 3.10%; net profit was 1.35 billion yuan, a year-on-year decrease of 3.40%

CR Double-Crane: The net profit for the third quarter was 374 million yuan, a year-on-year increase of 6.71%

CR Double-Crane's wholly-owned subsidiary WanHui Double-Crane recently obtained the Drug Registration Certificate for Alfacalcidol Soft Capsules issued by the National Medical Products Administration. This medication is indicated for the treatment of various calcium metabolism disorders caused by endogenous 1,25-dihydroxyvitamin D3 deficiency, including renal osteodystrophy, hypoparathyroidism, and osteoporosis

CR Double-Crane's subsidiary Alpha Calcifediol Soft Capsules has obtained a drug registration certificate

CR Double-Crane's wholly-owned subsidiary CR Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. recently received the Drug Registration Certificate for Bosentan Dispersible Tablets issued by the National Medical Products Administration. This medication is suitable for pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension (PAH), as well as adult PAH patients classified as WHO functional class II to IV

CR Double-Crane's subsidiary Bosentan dispersible tablets have obtained a drug registration certificate

CR Double-Crane announced that its wholly-owned subsidiary Anhui Double-Crane Pharmaceutical has obtained the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride issued by the National Medical Products Administration. This drug is mainly used for patients with non-ST segment elevation acute coronary syndrome to prevent early myocardial infarction and can be used for patients with acute myocardial infarction who are planned for direct PCI to reduce the occurrence of major cardiovascular events

CR Double-Crane: The hydrochloride injection of tirofiban and sodium chloride has obtained the drug registration certificate

CR Double-Crane's wholly-owned subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. recently received the approval notice for the supplementary application of peritoneal dialysis solution (lactate-G1.5% and G2.5%) issued by the National Medical Products Administration. This approval will help enhance the sales and competitiveness of this series of drugs in the market, primarily used for the treatment of patients with acute and chronic renal failure

CR Double-Crane's subsidiary's peritoneal dialysis solution (lactate) series of drugs has received the approval notice for the drug supplementary application

CR Double-Crane(600062.SH)